Company news
Roivant Sciences Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update
June 27, 2022
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
June 27, 2022
Roivant Sciences to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 on Tuesday, June 28, 2022
June 14, 2022
FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years
May 23, 2022
Roivant to Present at Upcoming Investor Conferences
May 18, 2022
Aruvant Announces Oral Presentation at American Society of Gene and Cell Therapy (ASGCT)
May 15, 2022
Roivant Appoints Chief Development Officer and Announces Multiple Collaborations in Targeted Protein Degradation
May 1, 2022
Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual Meeting
March 24, 2022
Roivant to Present at Targeted Protein Degradation Conference
March 10, 2022
Roivant Sciences Reports Financial Results for the Quarter Ended December 31, 2021 and Provides Business Update
February 13, 2022
Roivant to Report Financial Results for the Quarter Ended December 31, 2021 on Monday, February 14, 2022
February 6, 2022
Roivant Licenses Splicing Modulator and Announces Upcoming Presentation at 40th Annual J.P. Morgan Healthcare Conference
January 4, 2022
Roivant Sciences Reports Financial Results for the Quarter Ended September 30, 2021 and Provides Business Update
November 14, 2021
Roivant to Report Financial Results for the Quarter Ended September 30, 2021 on Monday, November 15, 2021
November 7, 2021
Roivant Discovery Announces 2021 Open Science Fellows
October 28, 2021
Calls
The 5 newest of 20 calls. Every call is listed under its year.
- Roivant Sciences (NASDAQ:ROIV) Q1 2026 Earnings Call
Aug 6, 2026
Transcript - Roivant Sciences (NASDAQ:ROIV) Q4 2025 Earnings Call
May 20, 2026
Transcript - Roivant Sciences (NASDAQ:ROIV) Q3 2025 Earnings Call
Feb 6, 2026
Transcript - Roivant Sciences (NASDAQ:ROIV) Q2 2025 Earnings Call
Nov 10, 2025
Transcript - Roivant Sciences (NASDAQ:ROIV) Q1 2025 Earnings Call
Aug 11, 2025
Transcript
Decks
The 5 newest of 21 decks. Every deck is listed under its year.
- Corporate Update (August 2026)
Corporate update · 27 slides · Aug 28, 2026
- Q1 2026 Earnings Presentation
Earnings · 22 slides · Aug 6, 2026
- Q3 2025 Earnings Presentation
Earnings · 32 slides · Feb 6, 2026
- Investor Day (December 2025)
Investor day · 192 slides · Dec 11, 2025
- Q2 2025 Earnings Presentation
Earnings · 31 slides · Nov 10, 2025